# US 2012/0252749 A1 · Methods of Treating Cancer with Glut Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252749 A1
- Document ID: US20120252749A1
- Status: Published application
- Kind: A1
- Application number: 13/435,625
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Assignees: Northwestern University
- Inventors: Malathy Shanmugam; Samuel K. McBrayer; Steven T. Rosen
- Web page: https://patentgrep.com/patent/US20120252749A1

## CPC

- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/69: Boron compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61P 35/00: Antineoplastic agents
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating cancer comprising administering inhibitors of glucose transporters (GLUTs) are provided. Methods of predicting whether a cancer will respond to treatment with a GLUT inhibitor also are provided.

## Claims

### Claim 1

A method of treating a GLUT-dependent cancer in a patient comprising administering a GLUT inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the GLUT-dependent cancer is selected from a GLUT4-dependent cancer, a GLUT8-dependent cancer, and a GLUT11-dependent cancer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the GLUT inhibitor is selected from a GLUT4 inhibitor, a GLUT8 inhibitor, and a GLUT11 inhibitor.

### Claim 4 (depends on 2)

The method of claim 2, wherein the GLUT dependent cancer is a GLUT4-dependent cancer.

### Claim 5 (depends on 3)

The method of claim 3, wherein the GLUT4-dependent cancer is multiple myeloma.

### Claim 6 (depends on 4)

The method of claim 4, wherein the GLUT inhibitor is a GLUT4 inhibitor.

### Claim 7 (depends on 6)

The method of claim 6, wherein the GLUT4 inhibitor is selected from ritonavir and indinavir.

### Claim 8 (depends on 7)

The method of claim 7, wherein the GLUT4 inhibitor is ritonavir.

### Claim 9 (depends on 2)

The method of claim 2, wherein the GLUT-dependent cancer is a GLUT8-dependent cancer.

### Claim 10 (depends on 9)

The method of claim 9, wherein the GLUT8-dependent cancer is multiple myeloma.

### Claim 11 (depends on 2)

The method of claim 2, wherein the GLUT-dependent cancer is a GLUT11-dependent cancer.

### Claim 12 (depends on 11)

The method of claim 11, wherein the GLUT11-dependent cancer is multiple myeloma.

### Claim 13 (depends on 1)

The method of claim 1, wherein the method further comprises administering a DNA damaging agent.

### Claim 14 (depends on 13)

The method of claim 13, wherein the DNA damaging agent is selected from doxorubicin, daunorubicin, idarubicin, valrubicin, and mitoxantrone.

### Claim 15 (depends on 14)

The method of claim 14, wherein the DNA damaging agent is doxorubicin.

### Claim 16 (depends on 1)

The method of claim 1, wherein the method further comprises administering a proteasome inhibitor.

### Claim 17 (depends on 16)

The method of claim 16, wherein the proteasome inhibitor is selected from bortezomib, disulfiram, epigallocatechin-3-gallate, and salinosporamide A.

### Claim 18 (depends on 17)

The method of claim 17, wherein the proteasome inhibitor is bortezomib.

### Claim 19 (depends on 1)

The method of claim 1, wherein the GLUT inhibitor is administered after the patient has fasted for at least 4 hours.

### Claim 20

A method of predicting whether a cancer patient will respond to treatment with a GLUT inhibitor, comprising detecting a GLUT in cancer cells from the patient, wherein an elevated level of the GLUT or a mislocalization of the GLUT indicates that the patient will respond to treatment with the GLUT inhibitor.
